BackOvid Therapeutics Overview
Ovid Therapeutics Inc

Ovid Therapeutics Target Price

Where could OVID trade next? Consensus target price: $6.5.

Get informed when a big investor buys or sells

+ Follow

Share Price

$2.4

Average Target Price

$6.50170.8% upside

2 analysts in the last 4 months

High: $8 | Low: $5

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-11H.C. WainwrightRaghuram Selvaraju$5108.3% upsideOpen
2026-09-03Roth CapitalBoobalan Pachaiyappan$8233.3% upsideOpen
2026-05-14Roth Capital$7191.7% upsideOpen
2026-04-09H.C. Wainwright$466.7% upsideOpen
2025-12-11Roth CapitalBoobalan Pachaiyappan$325% upsideOpen
2025-11-24H.C. Wainwright$216.7% downsideOpen
2024-07-02H.C. WainwrightRaghuram Selvaraju$325% upsideOpen
2024-05-20BTIGThomas Shrader$11358.3% upsideOpen
2024-05-14OppenheimerFrancois Brisebois$8233.3% upsideOpen

Ovid Therapeutics (OVID) FAQ

Ovid Therapeutics's target price stands at $6.5. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $6.5 for OVID implies 170.8% upside versus today's price ($2.4). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Ovid Therapeutics's target price evolved across reporting periods, while the comparison chart places OVID next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Ovid Therapeutics's reading of $6.5 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.